Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate
levels, but whether this translates into prevention of recurrent flares among patients with …

Importance Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-
glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of …

Background: Hyperuricemia is common in patients with type 2 diabetes mellitus and is
known to cause gout. Sodium–glucose cotransporter-2 (SGLT2) inhibitors prevent glucose …

Aims To pool the effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on gout and
to investigate the association of these effects with baseline serum uric acid (SUA), SUA …

Importance The use of sodium-glucose transport protein 2 (SGLT2) inhibitors is currently a
standard intervention in patients with type 2 diabetes (T2DM) and exerts favorable …

Purpose To collate the effect of SGLT2 inhibitors (SGLT2i) on adverse gout events in people
with type 2 diabetes mellitus (T2DM). Methods PubMed/MEDLINE, Embase, and Web of …

Purpose Sodium‐glucose cotransporter‐2 inhibitors (SGLT2‐I) are frequently used in type 2
diabetes and have recently been associated with lower rates of gout compared to glucagon …

Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory
arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions …

Despite an abundance of data generated in the last 5 years, it remains unclear whether
treating gout with urate-lowering therapy provides a cardiovascular benefit. Additionally …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on the management of gout. Methods …